uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Biomedical Radiation Sciences. (Vladimir Tolmachev)
(Vladimir Tolmachev)
Show others and affiliations
2012 (English)In: Tumor Biology, ISSN 1010-4283, E-ISSN 1423-0380, Vol. 33, no 3, 641-651 p.Article in journal (Refereed) Published
Abstract [en]

Affibody molecules are a class of small (ca.7 kDa) robust scaffold proteins with high potential as tracers for radionuclide molecular imaging in vivo. Incorporation of a cysteine-containing peptide-based chelator at the C terminus provides an opportunity for stable labelling with the radionuclide 99mTc. The use of a GGGC chelator at the C terminus has provided the lowest renal radioactivity retention of the previously investigated peptide-based chelators. Previously, it has also been demonstrated that replacement of the His6-tag with the negatively charged histidine-glutamate-histidine-glutamate-histidine-glutamate (HEHEHE)-tag permits purification of affibody molecules by immobilized metal ion affinity chromatography (IMAC) and provides low hepatic accumulation of radioactivity of conjugates site-specifically labelled at the C terminus using several different nuclides. We hypothesized that the combination of a HEHEHE-tag at the N terminus and a GGGC chelator at the C terminus of an affibody molecule would be a favourable format permitting IMAC purification and providing low uptake in excretory organs. To investigate this hypothesis, a (HE)3-ZHER2:342-GGGC affibody molecule was generated. It could be efficiently purified by IMAC and stably labelled with 99mTc. 99mTc-(HE)3-ZHER2:342-GGGC preserved specific binding to HER2-expressing cells. In NMRI mice, hepatic uptake of 99mTc-(HE)3-ZHER2:342-GGGC was lower than the uptake of the control affibody molecules, 99mTc-ZHER2:2395-VDC and 99mTc-ZHER2:342-GGGC. At 1 and 4 h after injection, the renal uptake of 99mTc-(HE)3-ZHER2:342-GGGC was 2–3-fold lower than uptake of 99mTc-ZHER2:2395-VDC, but it was substantially higher than uptake of 99mTc-ZHER2:342-GGGC. Further investigation indicated that a fraction of 99mTc was chelated by the HEHEHE-tag which caused a higher accumulation of radioactivity in the kidneys. Thus, a combination of a HEHEHE-tag and the GGGC chelator in targeting scaffold proteins was found to be undesirable in the case of 99mTc labelling due to a partial loss of site-specificity of nuclide chelation.

Place, publisher, year, edition, pages
2012. Vol. 33, no 3, 641-651 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-173743DOI: 10.1007/s13277-011-0305-zISI: 000303530200008PubMedID: 22249974OAI: oai:DiVA.org:uu-173743DiVA: diva2:525025
Available from: 2012-05-04 Created: 2012-05-04 Last updated: 2015-03-24Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Altai, MohamedOrlova, AnnaTolmachev, Vladimir
By organisation
Biomedical Radiation SciencesPreclinical PET Platform
In the same journal
Tumor Biology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 304 hits
ReferencesLink to record
Permanent link

Direct link